# To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

> **NCT05101135** · PHASE3 · UNKNOWN · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 256 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** JT-001
- **DRUG:** JT-001 Placebo

## Key facts

- **NCT ID:** NCT05101135
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-17
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 256 (ESTIMATED)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05101135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05101135, "To Evaluate the Efficacy and Safety of JT-001 add-on in Paatients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05101135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*